Epizyme (EPZM) Tops Q3 EPS by 3c

Epizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.56), $0.03 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $358 thousand versus the consensus estimate of $5.42 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Aspire Biopharma to acquire automotive supplier for $30 million
• Independent Bank receives regulatory approval for HCB Financial acquisition